We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Comparison of Pharmocodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in Type 1 Diabetes.
- Authors
Thorisdottir, Rannveig L.; Parkner, Tina; Jian-Wen Chen; Ejskjær, Niels; Christiansen, Jens S.
- Abstract
Studies comparing the clinical pharmacological characteristics of different formulations of an insulin analogue are few. We investigated the pharmacokinetic and pharmacodynamic profiles of four different formulations of the aspart insulin analogue: Pure Insulin Aspart (IAsp), Biphasic Insulin Aspart 30 (BIAsp30), Biphasic Insulin Aspart 50 (BIAsp50) and Biphasic Insulin Aspart 70 (BIAsp70), in patients with type 1 diabetes. The numbers indicate the proportion of short acting insulin aspart, while the rest is protaminated insulin aspart. The trial was an open-label, randomised cross-over study. Nineteen type 1 diabetic patients received identical doses of the 4 different insulin preparations on 4 separate visits. Long and intermediate acting insulin were terminated at least 24 hours before. Insulin injection and a standard meal were given in the morning following a night with glucose control by i.v. human insulin. Plasma glucose and serum insulin aspart were recorded from the morning and 12 hours ahead. During the first 4 hours of the study IAsp had statistically higher area under the curve for insulin aspart concentration (AUCins) as compared to the other 3 treatments, followed by BIAsp70, BIAsp50 and BIAsp30 (p<0.05). In the last 4 hours of the study BIAsp30 had significantly higher AUCins as compared to the other insulin preparations (p<0.05). The pharmacodynamics of the 4 different preparations reflected the pharmacokinetics. Thus, the highest area under the curve for glucose concentration (AUCglu) during the initial 4 hours was seen following BIAsp30 as compared to the other 3 treatments (p<0.05), while the highest AUCglu during the last 4 hours of the study was seen following IAsp as compared to BIAsp50 and BIAsp30 (p<0.05). Twenty-six hypoglycaemic interventions were needed during treatment with IAsp and only 8 for BIAsp30. When insulin aspart is formulated with protamine in different ratios the pharmacokinetic profiles are readily distinguishable. This difference in pharmacokinetics is reflected in the pharmacodynamic profiles of the 4 different preparations.
- Subjects
PHARMACOKINETICS; INSULIN; PHARMACODYNAMICS; DIABETES; BLOOD sugar; HYPOGLYCEMIA
- Publication
Diabetes, 2007, Vol 56, pA555
- ISSN
0012-1797
- Publication type
Article